Background: Although there exists potential risk of bleeding, extended 'lifelong' conventional-intensity [international normalized ratio (INR): 2.0-3.0] warfarin anticoagulation is recommended for unprovoked venous thromboembolism (VTE) patients because of risk of recurrent VTE. Whether long-term low-intensity (INR: 1.5-2.0) warfarin therapy reduced the risk of major bleeding without substantially lowered antithrombotic efficacy is not well understood. The aim of this study was to perform a systematic review and meta-analysis to evaluate the risk-benefits of low-intensity warfarin therapy.
| I NT ROD UCTI ON
When anticoagulant therapy is stopped after 3 to 6 months, patients with a first episode of unprovoked venous thromboembolism (VTE) have a much higher risk of recurrence than those with VTE provoked by a transient risk factor. [1] [2] [3] Although anticoagulation is effective in preventing recurrent events, the risk-benefit assessment and optimal duration of extended anticoagulation is uncertain. Extended use of conventional-intensity warfarin [a target international normalized ratio (INR) of 2.0-3.0] reduces recurrent VTE, 4, 5 but this approach has been associated with potential risk of major hemorrhage. 6 There is some evidence that low-intensity warfarin (a target INR of 1.5-2.0) may be effective because of a reduction of biochemical markers of coagulation (such as Ddimer) compared with conventional doses used for a prolonged period of time and also have lower risk of bleeding and less frequent monitoring. [7] [8] [9] Nevertheless, poor anticoagulation has been associated with increased risk for recurrence of unprovoked VTE as the very low anticoagulation level may enhance an underlying condition of hypercoagulability. 10 The direct oral anticoagulants (DOAC, dabigatran, rivaroxaban, apixaban and edoxaban) have been developed to overcome some of the limitations of warfarin, such as the need for regular therapeutic monitoring and dose adjustments, as well as drug or food interactions. 11 DOACs is popular because of safety and efficacy versus warfarin. In addition, low-dose DOAC therapy can prevent VTE recurrence as good as standard dose at risk of haemorrhage (moderate renal dysfunction, etc). 12 However, DOACs cannot yet completely replace warfarin in China, for instance, expensive cost, no medical insurance reimbursement and off-label for VTE treatment.
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In this study, we conducted this meta-analysis to summarize evidence on the risk-benefit assessment of warfarin in preventing recurrence of unprovoked VTE in the era of DOACs.
| M ATE RI ALS AN D ME THO DS

| Data sources and search strategy
The study was designed according to PRISMA statement (preferred reporting items for systematic reviews and metaanalyses). 13 PubMed, EMBASE and the Cochrane Collaboration databases were searched using the key words 'recurrence', 'warfarin', 'venous thromboembolism' to identify randomized control trials (RCTs) that evaluated risk (bleeding) and benefit (recurrent VTE and death) of low-intensity warfarin in preventing provoked VTE recurrence. Low-intensity warfarin regimen was defined as target INR of 1.5-2.0. Our search included articles published from database inception up to July 2016. The search was limited to English language articles. In addition, we individually searched references of retrieved articles and used PubMed's related articles' feature to identify studies not captured by our primary search design.
| Study selection
Unprovoked VTE was defined as symptomatic, proximal deep venous thrombosis (DVT) or pulmonary embolism (PE) that occurred in the absence of major risk factors. Such risk factors included fracture or plaster casting of a leg, hospitalization with confinement to bed for 3 or more days or surgery with general anaesthesia lasting longer than 30 minutes, all occurring within 3 months prior to thrombosis, and cancer that had been active within the previous 2 years. Inclusion criteria were: (a) unprovoked VTE; (b) 3 months of conventional-intensity warfarin. Patients were excluded if they had other indications for warfarin therapy; a contraindication to long-term warfarin therapy, including a high risk of bleeding; antiphospholipid antibodies or a life expectancy of less than 2 years. Patients with a hypercoagulable state (those with proven genetic predisposition or determined by coagulation testing) other than antiphospholipid antibodies were eligible. Reviews, editorials, letters, animal studies, case reports, observational studies and conference abstracts were excluded.
| Data extraction
The literature search, data extraction and methodological grading were performed in duplicate by 2 independent reviewers (R.J., Y.S.). Disagreements were resolved by consensus. We extracted data pertaining to characteristics of all studies (number of subjects, type of trial, inclusion/exclusion criteria, length of follow-up, primary endpoints, results). The pooled efficacy outcomes noted were recurrent VTE and major bleeding.
| Study outcomes and definitions
Efficacy outcomes were recurrent VTE (PE or DVT) and overall mortality. Safety outcomes were major bleeding, non-fatal major bleeding at a critical site, clinically relevant non-major bleeding, non-fatal intracranial bleeding, major gastrointestinal bleeding and fatal bleeding during anticoagulant treatment. Efficacy outcomes were risk of recurrent VTE in unprovoked VTE patients with low-intensity therapy versus conventional-intensity warfarin or placebo during long-term follow-up. Recurrent VTE was considered as cause of death if there was objective documentation, that is, by an autopsy, or if death could not be attributed to other causes and PE could not be ruled out. The safety outcomes were measures of bleeding in low-intensity therapy group versus conventional-intensity warfarin or placebo. The definition of major bleeding was similar for all included studies: overt and associated with a decrease in the haemoglobin level of 2 grams per decilitre or more, requiring transfusion of at least 2 units of blood, occurring in a critical site (intracranial, intraspinal, intraocular, pericardial, etc), or contributing to death. 14 
| Methodological quality
Risk of bias was assessed using domains suggested by the Cochrane Handbook of Systematic Reviews, specifically emphasizing sequence generation, allocation concealment, blinding, outcomes assessment and selective reporting for the included RCTs. 15 
| Data synthesis and statistical analysis
We conducted meta-analyses for comparisons when 2 or more studies reported the same outcome. Data were analysed using the Mantel-Haenszel fixed effects model, through RevMan 5.3 (The Cochrane Collaboration, Copenhagen, Denmark). Risk ratios with corresponding 95% confidence intervals (CI) were reported. Comparisons were performed for endpoints. Statistical heterogeneity was assessed and quantified using the Cochrane Q test and the I 2 statistic, respectively.
| Grading the quality of evidence
We used the GRADE approach cautiously to interpret the results. 16 Using the GRADE Profiler software, we imported the data from Review Manager 5.3 to create 'Summary of findings' tables and used it to guide our conclusions and recommendations. We assessed the quality of evidence by grading the quality of the studies at four levels as 'very low', 'low', 'moderate' and 'high' on the basis of risk of bias, inconsistency, indirectness, imprecision and publication bias. Quality ratings were made separately for each outcome. On the basis of study limitations; review authors made an overall judgment on whether the quality of evidence for an outcome warrants downgrading. The GRADE tables were revised as per the need of animal studies. As the domain of indirectness is only applicable and can be assessed solely with the human subjects; by default; we downgraded the quality of evidence by 1 (as serious indirectness). Also; the quality rating was downgraded to one level if the evidence was classified as 'serious' and to 2 levels if it was classified as 'very serious'. However, where potential limitations were not likely to lower confidence in the effect estimate, the evidence was not downgraded.
| RES U LTS
| Study selection
The initial search identified 311 records in PubMed, 599 unique records in EMBASE, 61 unique records in the Cochrane Database of systematic Reviews, resulting in a total of 971 references. Based on screening titles and abstracts, four studies 7, [17] [18] [19] were selected for full text reviewing ( Figure 1 ). The characteristics of all included studies are illustrated in Table 1 .
F IGUR E 1 Flow-chart of studies evaluated for inclusion in meta-analysis
| Characteristics of included RCTs
We included 4 RCTs comparing risks and benefits of lowintensity warfarin with conventional-intensity warfarin and placebo in unprovoked VTE patients who received at least 3-month conventional-intensity warfarin therapy, 2 of which evaluated low-intensity warfarin therapy versus conventionalintensity therapy, 17,19 2 of which evaluated low-intensity warfarin therapy versus placebo. 7, 18 Conventional-intensity therapy was defined as a target INR of 2.0-3.0. 7, 19 Lowintensity warfarin therapy was defined as INR of 1.5-1.9 17, 19 or 1.5-2.0.
7,18
3.3 | Meta-analysis: efficacy outcome
| Comparisons of low-intensity therapy versus conventional-intensity therapy
The relative risk (RR) of VTE recurrence with low-intensity warfarin therapy was higher than conventional-intensity therapy with no heterogeneity (P 5 .004, I 2 5 0%) (RR: 2.94; 95% CI: 1.40-6.24) (Figure 2 ). Recurrent VTE occurred in 27 of the 706 patients (3.8%) treated with low-intensity warfarin and in 9 of the 693 patients (1.3%) treated with conventional-intensity warfarin. In Kearon's study, 19 of 369 patients assigned to low-intensity therapy, 16 had VTE (1.9 per 100 person-years), as compared to 6 of 369 assigned to conventional-intensity therapy (0.7 per 100 person-years; hazard ratio (HR), 2.8; 95% CI: 1.1 to 7.0). In another study, 17 the rate of recurrence was 1.5% per patient-year among the 337 patients allocated to low-intensity therapy and 0.4% per patient-year among the 324 patients allocated to conventional-intensity therapy.
| Comparisons of low-intensity therapy versus placebo
When comparing low-intensity warfarin with placebo, recurrent VTE occurred in 28 of the 510 patients (5.5%) treated with low-intensity warfarin and in 75 of the 506 patients (14.8%) treated with placebo. The relative risk for lowintensity warfarin therapy demonstrated a significant decrease of 63% with no heterogeneity ([RR: 0.37, 95% CI: 0.24 to 0.56], P < .00001, I 2 5 0%) (Figure 3 ).
In Ridker et al' study, 7 of 253 patients assigned to placebo, 37 had recurrent venous thromboembolism (7.2 per 100 person-years), as compared with 14 of 255 patients assigned to low-intensity warfarin (2.6 per 100 person-years). However, Cushman' study 18 did not report the event rates
per patient life-years. Strength of evidence is presented in Figure 4 . According to the GRADE system, the strength of evidences was high for the efficacy outcome 
.1 | Comparisons of low-intensity therapy versus conventional-intensity therapy
Kearon et al's study 19 reported major bleeding episodes occurring in 9 patients assigned to low-intensity therapy (1.1 events per 100 person-years) and 8 patients assigned to conventional-intensity therapy (0.9 event per 100 personyears; HR, 1.2; 95% CI, 0.4 to 3.0). There was no significant difference in the frequency of overall bleeding between the 2 groups (HR, 1.3; 95% CI, 0.8 to 2.1). Another of Kearon's study 17 did not supply data regarding bleeding events.
| Comparisons of low-intensity therapy versus placebo
In Ridker's study, 7 2 patients had bleeding episodes necessitating hospitalization in the placebo group (0.4 per 100 person-years), and 5 patients had such episodes in the warfarin group (0.9 per 100 person-years) with non-significant difference (P 5 0.25). A total of 34 patients in the placebo group and 60 patients in the warfarin group reported minor bleeding or bruising (HR, 1.92; 95% CI, 1.26 to 2.93). In Cushman's study 18 did not supply data regarding bleeding events.
| D IS C US S I ON
The results of our meta-analysis identify that long-term lowintensity warfarin therapy is highly effective for preventing recurrent VTE than placebo but less effective than conventional-intensity warfarin therapy. The low-intensity warfarin regimen does not significantly reduce the risk of clinically important bleeding than conventional-intensity warfarin therapy but had no significant increased risk of major bleeding than placebo. CHEST Guideline and Expert Panel Report 20 for antithrombotic therapy for VTE recommends anticoagulation treatment for at least 3 months and then evaluate risks and benefits of extending therapy for patients with provoked VTE. For patients with unprovoked VTE and a low risk of bleeding or second episode of unprovoked DVT, the guidelines recommend indefinite anticoagulant therapy as long as the bleeding risk is not prohibitively elevated. 20 The optimal duration of anticoagulant therapy depends on additional risk factors for VTE recurrence as well as patient preferences regarding the burden of anticoagulation. Previous studies have used tools to predict the risk of VTE recurrence, which incorporate factors such as the presence of residual VTE, the location of the VTE, 21 age and sex, 22 as well as various laboratory 23 and imaging tests. 24 Besides, antiphospholipid antibody syndrome, 25 factor V Leiden mutation, 26 deficiencies of protein C, protein S and antithrombin 27 and elevated homocysteine levels 28 have been associated with significant VTE recurrence. Given the above discussed risks, patients with unprovoked VTE should receive 'lifelong' anticoagulation. Nevertheless, the guidelines recommend that extending the therapy must incorporate a balance of the VTE recurrence risk with the risk of bleeding associated with anticoagulant therapy 2, 20 and continue therapy until bleeding risks outweigh the benefits of reducing recurrence. 29 Long-term conventional-intensity warfarin may be not considered to carry a benefit-to-risk to be routinely recommended for patients with first unprovoked VTE event. First of all, prolonging initial therapy beyond 6 months does not reduce the recurrence risk once it is discontinued. 30 Furthermore, the mortality from a recurrent thrombotic event is thought to be similar to that of major bleeding. [4] [5] [6] Lastly, most clinicians are still unlikely to administer warfarin at conventional-intensity for more than 6 months to most patients following an unprovoked first VTE event. This is because of the need for regular laboratory monitoring and the lifestyle constraints associated with warfarin therapy that patients do not prefer, along with a fear of a major bleeding complication.
Given the efficacy of conventional-intensity warfarin in preventing recurrent VTE, it was logical to investigate whether low-intensity warfarin reduced the risk of major bleeding without substantially lowering its antithrombotic efficacy following initial therapy. Previous studies 8, 9 showed that an isolated low INR could potentially reduce thrombin generation from baseline and had no association with increased risk for VTE during anticoagulation. The Prevention of Recurrent Venous Thromboembolism (PREVENT) trial and the Canadian-based Extended Low-Intensity Anticoagulation for Thromboembolism (ELATE) trial were undertaken to evaluate low-intensity warfarin in patients with unprovoked VTE. 7, 19 Both studies provide evidence that low-intensity warfarin offers substantial protection against recurrent VTE. Although, the ELATE trial showed that conventional-intensity warfarin offers significantly greater protection against recurrent VTE than lowintensity therapy. The trial also demonstrated there was no significant difference in the frequency of major bleeding between low-intensity warfarin and placebo. Opposed to the ELATE trial, the PREVENT trial showed that low-intensity warfarin offers substantial protection against recurrent VTE than placebo. Low-intensity warfarin regimen can be monitored every other month with low rates of major bleeding complications, which can make long term warfarin therapy more appealing to some unprovoked VTE patients. In the PREVENT trial, there was no significant difference in the frequency of major and minor bleeding between conventional-intensity and lowintensity groups. Through our meta-analysis, we found long-term lowintensity warfarin therapy to be highly effective for preventing recurrent VTE than placebo but less effective than conventional-intensity warfarin therapy. Our results do not match the PREVENT trial 19 which reported recurrent VTE occurred in 4.33% patients on low-intensity warfarin and in 0.07% patients treated with conventional-intensity warfarin with significant hazard ratio. However, our result nearly matched the ELATE trial, 7 where a risk reduction of 64%.
Low-intensity warfarin was thus associated with a 48% reduction in the composite end point of recurrent VTE, major haemorrhage or death. The results highly recommend conventional-intensity warfarin therapy for unprovoked VTE patients without major bleeding risk, which also matches current guideline. 2 We believe low-intensity warfarin is a useful third option for management for some patients who do not require full-dose warfarin or wish to discontinue anticoagulation. While it has not been proven that the bleeding risk of low-intensity warfarin is less than conventional-intensity, it cannot be higher. Patients who accept conventional-intensity warfarin therapy are usually recommended to monitor INR every month by clinicians. INR monitoring of low-intensity warfarin can be carried out every other month, which is more acceptable for some patients than monthly monitoring for conventionaldose warfarin. 7, 8 Although low-intensity warfarin needs less frequent monitoring, it is associated with more recurrences and as dangerous as conventional dosing. However, in China, we have found that many patients have poor medical compliance when they administer conventional-intensity
The strength of evidences according to the GRADE. CI, confidence interal; RR, risk ratio; GRADE, an Emerging Consensus on Rating
Quality of Evidence and Strength of Recommendations warfarin because of many reasons. Perhaps, we may recommend extended low-intensity warfarin to unprovoked VTE patients who had no evidence of VTE after 6-to 12-month anticoagulation.
| L IM I TAT IO NS
Our study has potential limitations. First, the primary outcome included only 2 included studies that may not be clinically equivalent, although each has a high evidence-quality. However, we also performed random effects models which were consistent with the result of fixed effects model. Second, the average of anticoagulation was about 2 years. We could not estimate comparative efficacy of conventional-intensity therapy, low-intensity warfarin or placebo in patients with unprovoked VTE who received anticoagulation for longer time.
| C ONCL US I ONS
Both conventional-intensity warfarin therapy and lowintensity warfarin therapy offer substantial protection against recurrence, with long-term low-intensity warfarin therapy faring better than just placebo. Low-intensity warfarin therapy does not decrease significant overall bleeding events than conventional-intensity therapy but significant minor bleeding events than placebo.
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